scholarly journals No improvement in suboptimal vitamin A status with a randomized, double-blind, placebo-controlled trial of vitamin A supplementation in children with sickle cell disease

2012 ◽  
Vol 96 (4) ◽  
pp. 932-940 ◽  
Author(s):  
Kelly A Dougherty ◽  
Joan I Schall ◽  
Deborah A Kawchak ◽  
Michael H Green ◽  
Kwaku Ohene-Frempong ◽  
...  
2007 ◽  
Vol 98 (2) ◽  
pp. 422-430 ◽  
Author(s):  
R. A. Ayah ◽  
D. L. Mwaniki ◽  
P. Magnussen ◽  
A. E. Tedstone ◽  
T. Marshall ◽  
...  

Postpartum vitamin A supplementation of mothers and infants is recommended, but the efficacy has been questioned. In this double-blind, placebo-controlled trial, Kenyan mother–infant pairs were randomised to maternal vitamin A (400 000 IU) or placebo < 24 h postpartum, and infant vitamin A (100 000 IU) or placebo at 14 weeks. Milk retinol was determined at weeks 4, 14 and 26, and maternal and infant serum retinol at weeks 14 and 26. Infant retinol stores were assessed at week 26, using a modified relative dose response (MRDR) test. Among 564 women, serum retinol at 36 weeks gestation was 0·81 (sd 0·21) μmol/l, and 33·3 % were < 0·7 μmol/l. Maternal serum retinol was not different between groups, but milk retinol was higher in the vitamin A group: (0·67 v. 0·60 μmol/l; 0·52 v. 0·44 μmol/l; 0·50 v. 0·44 μmol/l at 4, 14 and 26 weeks, respectively). When expressed per gram fat, milk retinol was higher in the vitamin A group only at 4 weeks. Infant serum retinol was not different between groups. However, although most infants had deficient vitamin A stores (MRDR>0·06 %) at 26 weeks, vitamin A to infants, but not mothers, resulted in a lower proportion of infants with deficient vitamin A stores (69 v. 78 %). High-dose postpartum vitamin A supplementation failed to increase serum retinol and infant stores, despite modest effects on milk retinol. Infant supplementation, however, increased stores. There is a need for a better understanding of factors affecting absorption and metabolism of vitamin A.


The Lancet ◽  
2015 ◽  
Vol 385 (9975) ◽  
pp. 1324-1332 ◽  
Author(s):  
Honorati Masanja ◽  
Emily R Smith ◽  
Alfa Muhihi ◽  
Christina Briegleb ◽  
Salum Mshamu ◽  
...  

1996 ◽  
Vol 18 (4) ◽  
pp. 451
Author(s):  
S. Kuvihidila ◽  
D. Ode ◽  
L. Yu ◽  
R. Gardner ◽  
R. P. Warrier

2021 ◽  
Vol 8 (5) ◽  
pp. e334-e343
Author(s):  
Bart J Biemond ◽  
Anil Tombak ◽  
Yurdanur Kilinc ◽  
Murtadha Al-Khabori ◽  
Miguel Abboud ◽  
...  

2014 ◽  
Vol 89 (7) ◽  
pp. 709-713 ◽  
Author(s):  
Marvin E. Reid ◽  
Amal El Beshlawy ◽  
Adlette Inati ◽  
Abdullah Kutlar ◽  
Miguel R. Abboud ◽  
...  

Blood ◽  
1986 ◽  
Vol 67 (5) ◽  
pp. 1442-1447 ◽  
Author(s):  
LJ Benjamin ◽  
LR Berkowitz ◽  
E Orringer ◽  
VN Mankad ◽  
AS Prasad ◽  
...  

Abstract We have recently completed a double-blind, placebo-controlled, noncrossover study, the goal of which was to determine whether cetiedil citrate (cetiedil) could affect the course of vaso-occlusive crises in sickle cell disease. Patients, who presented to the emergency room at least 4 but no more than 24 hours after the onset of a painful vasoocclusive crisis severe enough to require hospitalization, were considered candidates for the study. Each patient received either placebo or cetiedil at one of the following three dosages: 0.2, 0.3, or 0.4 mg/kg body weight. The assigned drug dosage was given as a 30 minute intravenous infusion every 8 hours for 4 consecutive days. A total of 67 patients was enrolled in the study. Cetiedil, at its highest dosage (0.4 mg/kg body weight), was found to be significantly superior to placebo both in reducing the number of painful sites present on all 4 treatment days and in shortening the total time in crisis. No serious adverse reactions were observed during the course of the study. We conclude that cetiedil, given at a dosage of 0.4 mg/kg body weight, is therapeutically advantageous for sickle cell crisis.


Blood ◽  
2009 ◽  
Vol 114 (18) ◽  
pp. 3742-3747 ◽  
Author(s):  
Pablo Bartolucci ◽  
Tony El Murr ◽  
Françoise Roudot-Thoraval ◽  
Anoosha Habibi ◽  
Aline Santin ◽  
...  

Abstract Vaso-occlusive crisis (VOC) is the primary cause of hospitalization of patients with sickle-cell disease. Treatment mainly consists of intravenous morphine, which has many dose-related side effects. Nonsteroidal antiinflammatory drugs have been proposed to provide pain relief and decrease the need for opioids. Nevertheless, only a few underpowered trials of nonsteroidal antiinflammatory drugs for sickle-cell VOC have been conducted, and conflicting results were reported. We conducted a phase 3, double-blind, randomized, placebo-controlled trial with ketoprofen (300 mg/day for 5 days), a nonselective cyclooxygenase inhibitor, for severe VOC in adults. A total of 66 VOC episodes were included. The primary efficacy outcome was VOC duration. The secondary end points were morphine consumption, pain relief, and treatment failure. Seven VOC episodes in each group were excluded from the analysis because of treatment failures. No significant between-group differences were observed for the primary outcome or the secondary end points. Thus, although ketoprofen was well-tolerated, it had no significant efficacy as treatment of VOC requiring hospitalization. These findings argue against its systematic use in this setting.


1996 ◽  
Vol 18 (4) ◽  
pp. 450
Author(s):  
S. Kuvibidila ◽  
L. Yu ◽  
R. Gardner ◽  
D. Ode ◽  
G. Lane ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document